HomeInsightsStock Comparison

Cipla Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Cipla Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Last Updated on: Aug 27, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1579 as of 26 Aug 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 22.1 on March 2025 . This represents a CAGR of 0.08% over 6 yearsThe P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 16.9 on March 2025 . This represents a CAGR of -6.69% over 6 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 116434 crore on March 2025 . This represents a CAGR of 22.71% over 6 yearsThe Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 95465 crore on March 2025 . This represents a CAGR of 10.73% over 6 years.
  • The revenue of Cipla Ltd for the Jun '25 is ₹ 7216 crore as compare to the Mar '25 revenue of ₹ 7019 crore. This represent the growth of 2.8% The revenue of Dr Reddys Laboratories Ltd for the Jun '25 is ₹ 8862 crore as compare to the Mar '25 revenue of ₹ 9056 crore. This represent the decline of -2.14%.
  • The ebitda of Cipla Ltd for the Jun '25 is ₹ 2036 crore as compare to the Mar '25 ebitda of ₹ 1827 crore. This represent the growth of 11.47% The ebitda of Dr Reddys Laboratories Ltd for the Jun '25 is ₹ 2464 crore as compare to the Mar '25 ebitda of ₹ 2525 crore. This represent the decline of -2.43%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1292 crore over 9 quarters. This represents a CAGR of 12.23% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1409 crore over 9 quarters. This represents a CAGR of 0.15% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.05 % on March 2025 . This represents a CAGR of 9.87% over 6 yearsThe Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 12.47 % on March 2025 . This represents a CAGR of -2.07% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

Cipla Ltd News Hub

News

Cipla Ltd spurts 2.93%, gains for third straight session

Cipla Ltd is up for a third straight session in a row. The stock is quoting at Rs 1566.2, ...

Read more

13 Aug 2025 13:05

News

Cipla sees marginal decline in ESG rating

Cipla announced that SES ESG Research, a SEBI registered ESG Rating Provider (SES), has in...

Read more

11 Aug 2025 18:34

News

Cipla updates on USFDA cGMP inspection of its Bommasandra unit

Cipla announced that the United States Food and Drug Administration has classified the cur...

Read more

05 Aug 2025 09:46

News

Cipla's Bengaluru facility receives VAI classification from USFDA

The classification was communicated to the company via email on 4 August 2025. The inspect...

Read more

05 Aug 2025 14:05

News

Cipla gains after Q1 PAT rises 10% YoY to Rs 1,298 crore

Profit before tax (PBT) stood at Rs 1,769.93 crore in Q1 FY26, marking an 9.84% increase f...

Read more

25 Jul 2025 15:25

News

Cipla to conduct board meeting

Cipla will hold a meeting of the Board of Directors of the Company on 25 July 2025. Powere...

Read more

02 Jul 2025 10:19

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys Laboratories allots 4,160 equity shares under ESOS

Dr Reddys Laboratories has allotted 4,160 equity shares under ESOS on 20 August 2025. Powe...

Read more

20 Aug 2025 13:11

News

Dr Reddys Laboratories Ltd spurts 2.42%, rises for fifth straight session

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting...

Read more

13 Aug 2025 13:00

News

Dr Reddys Laboratories Ltd soars 1.07%

Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoti...

Read more

11 Aug 2025 13:05

News

Dr Reddy's Lab receives EIR from USFDA for Telangana API facility

The USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI) and co...

Read more

11 Aug 2025 14:44

News

Dr Reddys Laboratories Ltd soars 0.02%, rises for fifth straight session

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting...

Read more

29 Jul 2025 13:00

News

Dr Reddys Lab gains after Q1 PAT jumps 2% YoY to Rs 1,418 cr

Profit before tax (PBT) stood at Rs 1,905 crore in Q1 FY26, up 1.2% YoY EBITDA for the qua...

Read more

24 Jul 2025 12:17

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Dr Reddys Laboratories Ltd

Which company has a larger market capitalization, Cipla Ltd or Dr Reddys Laboratories Ltd?

Market cap of Cipla Ltd is 127,613 Cr while Market cap of Dr Reddys Laboratories Ltd is 105,437 Cr

What are the key factors driving the stock performance of Cipla Ltd and Dr Reddys Laboratories Ltd?

The stock performance of Cipla Ltd and Dr Reddys Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Dr Reddys Laboratories Ltd?

As of August 27, 2025, the Cipla Ltd stock price is INR ₹1579.85. On the other hand, Dr Reddys Laboratories Ltd stock price is INR ₹1263.35.

How do dividend payouts of Cipla Ltd and Dr Reddys Laboratories Ltd compare?

To compare the dividend payouts of Cipla Ltd and Dr Reddys Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions